Molecular Biomarkers for the Evaluation of Colorectal Cancer

Author:

Sepulveda Antonia R.1,Hamilton Stanley R.2,Allegra Carmen J.3,Grody Wayne4,Cushman-Vokoun Allison M.5,Funkhouser William K.6,Kopetz Scott E.7,Lieu Christopher8,Lindor Noralane M.9,Minsky Bruce D.10,Monzon Federico A.11,Sargent Daniel J.12,Singh Veena M.13,Willis Joseph14,Clark Jennifer15,Colasacco Carol16,Rumble R. Bryan17,Temple-Smolkin Robyn18,Ventura Christina B.16,Nowak Jan A.19

Affiliation:

1. From theDepartment of Pathology and Cell Biology, Columbia University, New York, NY; Departments of

2. Department of Pathology,

3. Division of Hematology and Oncology, University of Florida Medical Center, Gainesville;

4. Departments of Pathology and Laboratory Medicine, Pediatrics, and Human Genetics UCLA Medical Center, Los Angeles, CA;

5. Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha;

6. Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill;

7. Department of Gastrointestinal (GI) Medical Oncology,

8. Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver;

9. Department of Medical Genetics, Mayo Clinic, Scottsdale, AZ;

10. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston;

11. Castle Biosciences, Friendswood, TX;

12. Department of Health Sciences Research, Mayo Clinic, Rochester, MN;

13. Biocept, San Diego, CA;

14. Department of Pathology, Case Western Reserve University, Cleveland, OH;

15. ASCP Institute for Science, Technology, and Policy, American Society for Clinical Pathology, Washington, DC;

16. Laboratory and Pathology Quality Center, College of American Pathologists, Northfield, IL;

17. American Society of Clinical Oncology, Alexandria, VA;

18. Association for Molecular Pathology, Bethesda, MD;

19. Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY.

Abstract

Abstract Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

Funder

NIH

Publisher

Oxford University Press (OUP)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3